2017 Fiscal Year Final Research Report
Establishment of novel therapeutic system for renal cell carcinoma by pahrmacogenomics and transcriptomics
| Project/Area Number |
15K10573
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
成田 伸太郎 秋田大学, 医学部, 准教授 (40396552)
黄 明国 秋田大学, 医学(系)研究科(研究院), 助教 (60448503)
藤山 信弘 秋田大学, 医学部, 助教 (90603275)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 腎細胞癌 / 薬物動態 / 遺伝子多型 / 分子標的薬 / エクソソーム / マイクロRNA / サイトカイン |
|---|
| Outline of Final Research Achievements |
We analyzed pharmacokinetics and polymorphisms of 8 genes in 46 patients with metastatic RCC (mRCC) who were treated with axitinib. Axitinib level in patients with UGT1A1 poor metabolisers were signifcantly higher than others. The overall survival (OS) in patients with C0>5 ng/mL was signifcantly better than that in others. Genetic polymorphisms in UGT1A1 were signifcantly associated with the plasma axitinib level.
Furthermore, we measured serum concentrations of 34 cytokines in 44 mRCC patients treated with axitinib. PFS and OS of those patients in whom serum PAI-1 level decreased after the treatment was significantly extended. The multivariate analysis showed that declined serum PAI-1 after the treatment was a independent predictive marker of PFS and OS.
|
| Free Research Field |
泌尿器癌
|
